This page contains Forward Looking Statements made as of October 19, 2016.*


Vepoloxamer (MST-188), an investigational agent, is purified poloxamer 188, a nonionic, block copolymer comprised of a central linear chain of hydrophobic polyoxypropylene flanked on both sides by linear hydrophilic polyoxyethylene chains. Studies have shown that vepoloxamer’s mechanism of action is biophysical and driven by its ability to modulate cell membrane surface tension. Its hydrophobic polyoxypropylene core is believed to adhere to hydrophobic domains exposed on damaged cell membranes, restoring membrane integrity and reducing surface tensions that otherwise promote pathological adhesive interactions.  Data suggest vepoloxamer does not interact with healthy cell membranes, which have a hydrophilic exterior surface. As the damaged area of the cell membrane repairs, vepoloxamer is removed from the cell surface and ultimately is excreted from the body, unchanged, primarily in the urine.

We are currently evaluating partnership opportunities for vepoloxamer in ischemic stroke (phase 2-ready).

*Forward-Looking Statements: Any statement contained in this page that is not a statement of historical fact should be considered a forward-looking statement that speaks only as the date of the post in which it is made. Forward-looking statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Please see the Terms and Conditions of Use page of this website for more information about forward-looking statements.